



Fax completed form to: (855) 840-1678

If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

Botox (botulinum toxin type A)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication requested: <input type="checkbox"/> Botox 50 unit vial <input type="checkbox"/> Botox 100 unit vial <input type="checkbox"/> Botox 200 unit vial Total Dose Requested: Frequency of Administration: Quantity: List all muscles/sites that Botox will be injected at and list number of units being injected (e.g 30 units in trapezius muscle): 1. _____ units into _____ 6. _____ units into _____ 2. _____ units into _____ 7. _____ units into _____ 3. _____ units into _____ 8. _____ units into _____ 4. _____ units into _____ 9. _____ units into _____ 5. _____ units into _____ 10. _____ units into _____ Duration of therapy: J-Code: CPT Code: ICD10: Is this for new therapy or continuation of therapy? If your patient has already begun treatment with drug samples of Botox, please choose "new start of therapy". <input type="checkbox"/> new therapy <input type="checkbox"/> continuation of therapy (if currently taking for Migraine Headache Prevention) Is documentation being provided that if the patient is currently taking Botox for migraine headache prevention, the patient has had a significant clinical benefit from the medication as determined by the prescriber? Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Botox was initiated. - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. Yes <input type="checkbox"/> No <input type="checkbox"/>					
Where will this medication be obtained? <input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Other (please specify): **Cigna's nationally preferred specialty pharmacy					
**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557					
Facility and/or doctor dispensing and administering medication: Facility Name: State: Tax ID#: Address (City, State, Zip Code):					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Please provide the diagnosis Botox is being used to treat and answer additional below questions as necessary. Diagnosis: _____ Diagnoses are grouped by condition type (Neurological, Gastrointestinal, Exocrine, Ophthalmologic, and Urologic).					

Neurologic Conditions	
<input type="checkbox"/>	Blepharospasm (including blepharospasm associated with dystonia, benign essential blepharospasm, seventh (VII) nerve disorders) Is documentation being provided that the patient has intermittent or sustained closure of the eyelids caused by involuntary contractions of the orbicularis oculi muscle? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. Yes <input type="checkbox"/> No <input type="checkbox"/> Is the requested medication prescribed by, or in consultation with, a neurologist or ophthalmologist? Yes <input type="checkbox"/> No <input type="checkbox"/>
<input type="checkbox"/>	Cervical dystonia, including spasmodic torticollis Is documentation being provided that the patient has a diagnosis of cervical dystonia?- Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. Yes <input type="checkbox"/> No <input type="checkbox"/> Is documentation being provided that the patient has sustained head torsion and/or tilt with limited range of motion in the neck?- Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. Yes <input type="checkbox"/> No <input type="checkbox"/> Is the requested medication prescribed by, or in consultation with, a pain medicine specialist, neurologist, or physical medicine and rehabilitation physician? Yes <input type="checkbox"/> No <input type="checkbox"/>
<input type="checkbox"/>	Migraine Headache Prevention PRIOR to Botox, how many HEADACHE days per month is/was your patient experiencing? _____ PRIOR to Botox, how many hours per day do/did your patient's headaches last? _____ Per the information given above, PRIOR to initiation of Botox therapy, does/did the patient have 15 or more migraine headache days per month with each headache lasting four hours per day or longer? Yes <input type="checkbox"/> No <input type="checkbox"/> Is the requested medication being prescribed by, or in consultation with, a neurologist, or headache specialist? Yes <input type="checkbox"/> No <input type="checkbox"/>
<input type="checkbox"/>	Essential tremor (head, neck, hand, and voice) Has the patient tried at least one other pharmacologic therapy for the treatment of tremors? Notes: Examples of pharmacologic therapies for essential tremor include primidone, propranolol, atenolol, sotalol, alprazolam, gabapentin, topiramate. Yes <input type="checkbox"/> No <input type="checkbox"/>
<input type="checkbox"/>	Focal Dystonias Check all that apply: <input type="checkbox"/> Focal Upper Limb Dystonia (example: focal hand dystonia) <input type="checkbox"/> Laryngeal Dystonia (Spasmodic Dysphonia) <input type="checkbox"/> Oromandibular Dystonia (orofacial dystonia)
<input type="checkbox"/>	Hemifacial Spasm Limb spasticity Which of the following best describes the patient's condition/reason for treatment? <input type="checkbox"/> Lower limb spasticity (LLS) <input type="checkbox"/> Upper limb spasticity (ULS) <input type="checkbox"/> Both upper and lower limb spasticity
<input type="checkbox"/>	Other (please specify):
Gastrointestinal Conditions	
<input type="checkbox"/>	Achalasia
<input type="checkbox"/>	Chronic anal fissure
<input type="checkbox"/>	Other (please specify):

Exocrine Conditions	
<input type="checkbox"/>	Chronic Sialorrhea
<input type="checkbox"/>	Hyperhidrosis Check all that apply: <input type="checkbox"/> primary axillary hyperhidrosis <input type="checkbox"/> Primary Palmar/Plantar/Facial Hyperhidrosis <input type="checkbox"/> gustatory sweating (Frey's syndrome) <u>For primary axillary hyperhidrosis:</u> Is the patient's hyperhidrosis significantly interfering with the ability to perform age-appropriate activities of daily living? Yes <input type="checkbox"/> No <input type="checkbox"/> Has the prescriber excluded secondary causes of hyperhidrosis? Yes <input type="checkbox"/> No <input type="checkbox"/> Has the patient tried at least one topical prescription agent for axillary hyperhidrosis for at least 4 weeks and experienced inadequate efficacy or significant intolerance? Notes: Examples of prescription topical agents for the treatment of axillary hyperhidrosis include Xerac AC (aluminum chloride 6.25% topical solution), Drysol (aluminum chloride 20% topical solution), Qbrexza (glycopyrronium cloth 2.4% for topical use), Sofdra (glycopyrronium 12.45% topical gel). Yes <input type="checkbox"/> No <input type="checkbox"/> <u>For Primary Palmar/Plantar/Facial Hyperhidrosis:</u> Is the patient's hyperhidrosis significantly interfering with the ability to perform age-appropriate activities of daily living? Yes <input type="checkbox"/> No <input type="checkbox"/> Has the prescriber excluded secondary causes of hyperhidrosis? Yes <input type="checkbox"/> No <input type="checkbox"/> Has the patient tried at least one topical agent for axillary hyperhidrosis for at least 4 weeks and experienced inadequate efficacy or significant intolerance? Notes: Examples of topical agents for the treatment of hyperhidrosis include topical aluminum chloride antiperspirants. Yes <input type="checkbox"/> No <input type="checkbox"/>
<input type="checkbox"/>	Other (please specify):
Ophthalmologic Conditions	
<input type="checkbox"/>	Strabismus
<input type="checkbox"/>	Other (please specify):
Urologic Conditions	
<input type="checkbox"/>	Overactive Bladder with Symptoms of Urge Urinary Incontinence, Urgency, and Frequency (Adult) Has the patient tried at least one other pharmacologic therapy for the treatment of overactive bladder (OAB)? Notes: Examples of other OAB pharmacologic therapies include a beta-3 adrenergic agonist or an anticholinergic medication. Yes <input type="checkbox"/> No <input type="checkbox"/>
<input type="checkbox"/>	Urinary Incontinence Due to Detrusor Overactivity Associated with a Neurological Condition (Adult) Has the patient tried at least one other pharmacologic therapy for the treatment of urinary incontinence? Notes: Examples of other pharmacologic therapies for urinary incontinence include a beta-3 adrenergic agonist or an anticholinergic medication. Yes <input type="checkbox"/> No <input type="checkbox"/>
<input type="checkbox"/>	Neurogenic Detrusor Overactivity (NDO), Pediatric Has the patient tried at least one other pharmacologic therapy for the treatment of neurogenic detrusor overactivity (NDO)? Notes: Examples of other NDO pharmacologic therapies include a beta-3 adrenergic agonist or an anticholinergic medication. Yes <input type="checkbox"/> No <input type="checkbox"/>
<input type="checkbox"/>	Other (please specify):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v071525

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005